Summarized by Masters of Longevity from Longevity Technology.
A cardiology trial report examining whether a new therapy that lowers Lp(a) translates into fewer heart attacks and strokes; useful if you want a concise update on what the study tested and why it mattered.
Key Takeaways
- Pelacarsen substantially lowered Lp(a) blood levels but did not reduce major cardiovascular events versus placebo.
- The Phase III Lp(a)HORIZON trial enrolled over 8,000 patients with established heart disease and elevated Lp(a).
- Lowering a biomarker like Lp(a) does not automatically translate into reduced clinical cardiovascular risk.
